Exact Sciences Corporation Aktie News

Full disclosure, I'm not a tremendous fan of Cathie Wood. Generally, I think she makes some terrible picks.

Exact Sciences' most important product is still driving top-line growth. The company is working on several other exciting diagnostic tests.

ROCHESTER, Minn. & MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences and Mayo Clinic advance precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients.

Exact Sciences stock surged Tuesday after the company's colon cancer-screening rival, Freenome, unveiled the results of a pivotal study.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Comprehensive Cancer Center, reported on data showing high sensitivity and specificity for the non-endoscopic Oncoguard® Esophagus test that is currently in development for the detection of esophageal adenocarcinoma (EAC) and its pre...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2024 Gallup Exceptional Workplace Award (GEWA). This award recognizes the most engaged workplace cultures in the world. Gallup created the Exceptional Workplace Award to identify excellence and celebrate organizations that incorpor...

Identifying growth stocks to buy at this time, especially at their 52-week lows, can be challenging. With the market trending upward, current optimism suggests fewer stocks near their lows.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The New England Journal of Medicine. The peer-reviewed study, "Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening", will also appear in the journal's March 14, 2024 print issue....